Bonomi, P. D.Gandara, D.Hirsch, F. R.Kerr, K. M.Obasaju, C.Paz-Ares, L.Bellomo, C.Bradley, J. D.Bunn, P. A.Culligan, M.Jett, J. R.Kim, E. S.Langer, C. J.Natale, R. B.Novello, S.Pérol, M.Ramalingam, S. S.Reck, M.Reynolds, C. H.Smit, E. F.Socinski, M. A.Spigel, D. R.Vansteenkiste, J. F.Wakelee, H.Thatcher, N.2018-11-192018-11-192018-08-01Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, 'Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer', Annals of Oncology, vol. 29, no. 8, pp. 1701-1709. https://doi.org/10.1093/annonc/mdy1960923-7534http://hdl.handle.net/2164/11465Writing assistance was funded by Eli Lilly and Company (no grant numbers apply).9261521engSDG 3 - Good Health and Well-beingEGFR-directed monoclonal antibodiesNon-small-cell lung cancerSquamous cell lung cancerR MedicineHematologyOncologyRJournal item10.1093/annonc/mdy196https://www.scopus.com/pages/publications/85055507014